A Pharmacokinetic/Pharmacodynamic Study of RO5185426 in Previously Treated Patients With Metastatic Melanoma

NCT01107418 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

52

Enrollment

INDUSTRY

Sponsor class

Conditions

Malignant Melanoma

Interventions

DRUG: RO5185426
DRUG: RO5185426
DRUG: RO5185426
DRUG: RO5185426
DRUG: RO5185426

Sponsor

Hoffmann-La Roche